Neurometrix, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NURO
Neurometrix, INCNeuroMetrix's third quarter results show a significant revenue decline primarily due to changes in Medicare Advantage reimbursements, while the company continues its strategic review process.
NURO
Neurometrix, INCNeuroMetrix's second quarter 2024 revenue declined significantly due to changes in Medicare Advantage reimbursements, while the company continues its strategic review to maximize shareholder value.
NURO
Neurometrix, INCNeuroMetrix's Q1 2024 results show a significant revenue decline and increased net loss, alongside a strategic review and workforce reduction.